Shareholder Information

Shares Issued

As at 5 June 2020, the number of shares in issue was 433,636,255.

Significant Shareholders

As at 5 June 2020

Shareholder Number Ordinary
Shares %
Craig Auringer 23,837,250 5.50
Samantha Bauer 17,996,487 4.15
Mark Hawtin 12,668,570 2.92

Director Shareholdings

As at 5 June 2020

Director Number Ordinary
Shares %
Alexis Sandler 75,090,685 17.32
Dr Vladislav Sandler 41,544,677 9.58
Peter Redmond 5,596,270 1.29

Shares Not In Public Hands

Insofar as it is aware, as at 5 June 2020, 50.01% of the Company’s securities were not in public hands.

UK City Code On Takeovers And Mergers

The Company is subject to the provisions of the City Code on Takeovers and Mergers.

Shareholder Circulars

12 May 2020 Notice of AGM to be held on 4 June 2020

As the 2020 AGM was held as a closed meeting due to COVID-19 public health restrictions on travel and meetings, shareholders were invited to submit questions to the directors relating to the business of the AGM in advance. While the company continues to engage with shareholders, no such questions were formally submitted. An operational update was published as part of the announcement of AGM results. The Company looks forward to re-establishing full shareholder engagement as soon as practical, and continues to publish relevant news promptly.

Financial Reports

Annual and Half Year Reports, together with historical AGM notices and proxy voting forms, may be found here: Annual and Half Year Reports.

Other Exchanges And Trading Platforms

Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.